RxDoctor Payments Data

Aaron Strobel, MD

Internal Medicine · Little Rock, ARNPI 1689917163

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (46.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 60.8% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2020 at $16,498 and has fallen 77.5% since, to $3,718 in 2025. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,194in general payments, 2019–2025

Across 231 payments — averaging $139.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$20K
  • Edwards Lifesciences$4K
  • Abbott$4K
  • Boston Scientific$2K
  • Shockwave Medical, Inc$859
  • Astellas Pharma US Inc$188
  • plus $1K from 20 others

What the payments were for

  • Grants$15,00047%
  • Travel & lodging$6,81921%
  • Food & beverage$9,44629%
  • Education$9293%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,194 in reported general payments places this provider in the 95th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$536,450
Medicare patients
1,508
Services billed
7,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban410$351,749
EntrestoSacubitril/Valsartan212$190,187
JardianceEmpagliflozin50$44,512
Repatha SureclickEvolocumab72$43,963
XareltoRivaroxaban36$30,697
BrilintaTicagrelor44$30,401
Ezetimibe413$8,675
VascepaIcosapent Ethyl21$7,075
Repatha SyringeEvolocumab12$6,416
Metoprolol Succinate440$6,340
Ranolazine ErRanolazine60$5,937
Atorvastatin Calcium530$5,109
Rosuvastatin Calcium344$4,342
Prasugrel Hcl35$3,155
Diltiazem 24hr Er (Cd)Diltiazem Hcl78$3,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$351,749410 claims
NovartisEntresto$122$190,187212 claims
Boehringer IngelheimJardiance$13$44,51250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →